PUBLISHER: DelveInsight | PRODUCT CODE: 1226649
PUBLISHER: DelveInsight | PRODUCT CODE: 1226649
"XELJANZ Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XELJANZ for Rheumatoid Arthritis in the 7MM. A detailed picture of the XELJANZ for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the XELJANZ for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XELJANZ market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
Tofacitinib is marketed by Pfizer under the brand name XELJANZ. It is an inhibitor of JAK, a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe Rheumatoid Arthritis (RA) that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Some of the prominent adverse effects include nausea and headache, as well as more serious immunologic and hematological adverse effects.
It may also be used as an adjunct to methotrexate therapy or other non-biologic disease-modifying antirheumatic drugs (DMARDs) when methotrexate alone is not sufficient. However, it is not recommended in patients who have a history of chronic or recurrent infections or in the presence of an active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster, and urinary tract infections).
The recommended adult daily dosage of XELJANZ and XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, in patients with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia, or anemia.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
XELJANZ Analytical Perspective by DelveInsight
This report provides a detailed market assessment of XELJANZ in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of XELJANZ for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions